Holen Sie sich die Stockscreener-App
6.72
4.41%
-0.31
Handel nachbörslich:
6.68
-0.04
-0.60%
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst CallSlideshow (NASDAQ:DTIL) 2026-03-18 - Seeking Alpha
Jones Trading reiterates Precision BioSciences stock rating on DMD trial design - Investing.com
Precision BioSciences Announces PBGENE-DMD Investor Update and Highlights ARCUS Gene Editing Platform – March 2026 - Minichart
Precision BioSciences Highlights PBGENE-DMD Program and Trial - TipRanks
Quarterly Risk: How volatile is Precision BioSciences Inc stockEarnings Overview Report & Daily Stock Trend Watchlist - baoquankhu1.vn
Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN
Precision BioSciences (DTIL) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Precision BioSciences Stock (ISIN: US74019P1084) Surges on Q4 Profit Turnaround Amid Analyst Upgrade - AD HOC NEWS
Precision BioSciences (NASDAQ:DTIL) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative - simplywall.st
Precision BioSciences Inc buy Jefferies Financial Group Inc. - sharewise.com
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Jefferies cuts Precision BioSciences stock price target on valuation - Investing.com
Precision BioSciences Advances PBGENE-DMD Trial, Putting New Focus on Duchenne Gene Therapy - TipRanks
Jefferies Maintains Buy for Precision BioSciences (DTIL) March 13, 2026 - Meyka
Precision BioSciences (NASDAQ:DTIL) Trading Up 12.1%Here's Why - MarketBeat
Precision BioSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Precision BioSciences (DTIL) Swings to $1.05 EPS in Q4, Reversing $2.22 Year-Ago Loss - AlphaStreet
Precision BioSciences (DTIL) Exceeds Expectations for Q4 Earnings and Revenue - Bitget
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Bus - PharmiWeb.com
Precision BioSciences presents preclinical data on DMD therapy By Investing.com - Investing.com Nigeria
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precision BioSciences (DTIL) Surpasses Q4 Revenue Expectations - GuruFocus
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Surges After Strong Q4 Earnings Bea - GuruFocus
Precision BioSciences Q4 2025 Earnings: $20.1M Profit on $34.2M RevenueNews and Statistics - IndexBox
Precision Biosciences 2025 10-K: Revenue $34.3M, GAAP net loss $(45.7M) - TradingView
Precision BioSciences (NASDAQ: DTIL) turns Q4 profit and extends cash runway to 2028 - Stock Titan
Precision BioSciences: Q4 Earnings Snapshot - Barchart.com
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update - Yahoo! Finance Canada
Precision BioSciences receives patent allowances for hepatitis B program By Investing.com - Investing.com Canada
Precision BioSciences (DTIL) Secures Key Patent Allowances for P - GuruFocus
Precision BioSciences receives patent allowances for hepatitis B program - Investing.com Australia
Precision BioSciences, Inc. Receives U.S. Patent Allowances Covering PBGENE-HBV Program - marketscreener.com
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program - BioSpace
Precision BioSciences receives U.S. patent allowances covering the PBGENE-HBV program - marketscreener.com
Patent nod through 2044 backs hepatitis B gene edit program - Stock Titan
H.C. Wainwright Sticks to Its Buy Rating for Precision BioSciences (DTIL) - The Globe and Mail
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026 - BioSpace
Precision BioSciences Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Precision BioSciences (DTIL) Presents Promising Preclinical Data for DMD Therapy - GuruFocus
Precision BioSciences presents preclinical data on DMD therapy - Investing.com
One-time gene edit keeps dystrophin flowing 9 months in DMD mice - Stock Titan
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026 - BioSpace
Precision BioSciences to Report Q4 and Fiscal Year 2025 Results - National Today
Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event - BioSpace
Precision BioSciences Says PBGENE-DMD Receives FDA Fast Track Designation - marketscreener.com
Precision BioSciences stock jumps on FDA Fast Track status By Investing.com - Investing.com Canada
FDA Grants Fast Track Status to Precision BioSciences' (DTIL) PB - GuruFocus
FDA Fast Tracks experimental Duchenne muscular dystrophy therapy - Stock Titan
Forecast Cut: Is Precision BioSciences Inc gaining market shareWeekly Trade Recap & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Earnings Beat: Is Precision BioSciences Inc stock trending bullishPortfolio Update Summary & Real-Time Volume Triggers - baoquankhu1.vn
1.20%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):